- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00482066
Abatacept in ANCA Associated Vasculitis (ABAVAS)
A Pilot Study Examining the Effect of Abatacept in ANCA Associated Vasculitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The drugs that are normally used to treat patients with AAV are quite effective, but up to 20% of patients relapse within 18 months. The drugs used can also have significant side effects. Abatacept, also known as CTLA4Ig, acts by blocking vital costimulatory signals required for T lymphocytes to be activated. As ANCA associated vasculitis is believed to be an autoimmune condition and dependent on autoreactive T cells, there is some reason to believe this drug would be effective. Abatacept has already received a license by the FDA for use in Rheumatoid arthritis where it has proven to be effective even in patients unresponsive to Etanercept (TNF blockade).
120 patients with AAV will be invited to take part in this study, from hospitals in the UK and Europe. The patients will receive standard therapy with methotrexate and steroids as well as 12 months of abatacept or placebo. They will be followed for a further 12 months.
The primary objective of this study is to assess the relapse rate over 24 months, in patients with acute AAV, presenting at first diagnosis or relapse, in the two arms of the study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, W12 0NN
- Imperial College London, Hammersmith Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Acute AAV, presenting at first diagnosis or relapse, defined by clinical presentation
- ANCA positivity (anti-MPO or anti-PR3 positive)
- BVAS score of > 8.
Exclusion Criteria:
- Severe life-threatening disease, i.e. lung haemorrhage at the time of presentation, renal impairment with SCr>150 micromol/l, or severe CNS dysfunction thought to be due to vasculitis.
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological or cerebral disease, or other medical conditions that might place the subject at unacceptable risk for participation in this study.
- Any other non-vasculitic multisystem autoimmune disease
- Serious acute or bacterial infection unless treated and completely resolved with antibiotics prior to enrolment
- With any severe chronic or recurrent bacterial infection
- With Hepatitis B or C or HIV
- With Herpes zoster infection that resolved less than 2 months prior to enrolment
- Subjects who have received any live vaccines within 3 months of the first dose of study medication or who will have need of a live vaccine at any time in the year following enrolment
- Subjects with current clinical or laboratory evidence of active or latent tuberculosis (TB) and subjects with a history of active TB treated within the last 3 years
- With any previous malignancy, with the exception of non-melanoma skin malignancies, adequately treated previously
- Subjects with a mammogram that is suspicious for malignancy and in whom the possibility of malignancy cannot be reasonably excluded following additional evaluations. Mammograms (females only) must be performed within 6 months of study entry or if documentation is not on file.
- With MTX treatment in prior 3 months
- Subjects with prior therapy with rituximab, anti-TNF therapy, or IL-1 receptor antagonists within last year or cyclophosphamide within last six months
- Subjects with a history of intolerance to methotrexate
- Subjects who have at any time received treatment with abatacept
- Subjects who have received treatment with any investigational drug within 28 days (or less than 5 terminal half-lives of elimination) of the Day 1 dose
- Subject receiving approved or investigational biologics
Subjects with any of the following laboratory values:
- Hgb < 8.5 g/dL.
- WBC < 3,000/mm3 (3 x 109/L)
- Platelets < 100,000/mm3 (100 x 109/L).
- Serum ALT or AST > 2 times upper limit of normal.
- Any other laboratory test results that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study.
- Subjects participating concurrently in another clinical trial
- Pregnancy, breast feeding or inadequate contraception if female.
- Allergy to a study medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Abatacept (Orencia)
|
500mg for patients under 60kg 750mg for patients 60-100kg 1g for patients>100kg given as i.v. infusion over 30 minutes at day 0, 14, 28 and then monthly for a further 11 months 914 infusions in total) placebo groups receive saline only I.v. |
Placebo Comparator: 2
saline placebo
|
500mg for patients under 60kg 750mg for patients 60-100kg 1g for patients>100kg given as i.v. infusion over 30 minutes at day 0, 14, 28 and then monthly for a further 11 months 914 infusions in total) placebo groups receive saline only I.v. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Relapse rate over 24 months.
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patients in sustained remission (i.e. remission at 3 months sustained for 6 months and remission at 6 months sustained for a further 12 months);
Time Frame: 2 years
|
2 years
|
Time to remission;
Time Frame: 2 years
|
2 years
|
The average steroid dosage at 6 months, 1 year, 18 months and 2 years in abatacept and placebo groups respectively;
Time Frame: 2 years
|
2 years
|
Time to ANCA negativity by immunofluorescence or negative anti-PR3 or anti-MPO Ab test by ELISA.
Time Frame: 2 years
|
2 years
|
Proportion of patients defaulting to cyclophosphamide (MMF, azathioprine or other rescue) therapy.
Time Frame: 2 years
|
2 years
|
Proportion of patients unable to stick with trial protocol.
Time Frame: 2 years
|
2 years
|
Degree of chronic disease activity
Time Frame: 2 years
|
2 years
|
Health related quality of life
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Alan Salama, Imperial College London
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Autoimmune Diseases
- Systemic Vasculitis
- Vasculitis
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Immune Checkpoint Inhibitors
- Abatacept
Other Study ID Numbers
- cro632
- 2006-001859-35 (EudraCT Number)
- BMS protocol No: IST110 (Other Grant/Funding Number: Bristol Myers Squib funder)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ANCA-associated Vasculitis
-
University Hospital, Strasbourg, FranceRecruiting
-
Xiangya Hospital of Central South UniversityThe Third Xiangya Hospital of Central South University; Hunan Provincial People... and other collaboratorsRecruiting
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)TerminatedANCA-Associated VasculitisUnited Kingdom
-
Chinese SLE Treatment And Research GroupThe First Affiliated Hospital of Anhui Medical University; Shanghai Zhongshan... and other collaboratorsRecruitingANCA Associated Vasculitis | Maintenance TherapyChina
-
University Hospital Birmingham NHS Foundation TrustMerck Sharp & Dohme LLCRecruitingANCA Associated VasculitisUnited Kingdom
-
University Hospital, BrestNot yet recruitingOccupational Diseases | ANCA Associated Vasculitis | Environmental ExposureFrance
-
Shanghai Zhongshan HospitalCompletedDrug Use | ANCA Associated Vasculitis | JAK-STAT Pathway DeregulationChina
-
Chinese SLE Treatment And Research GroupPeking Union Medical College HospitalRecruitingANCA Associated VasculitisChina
-
ChemoCentryxCompletedA Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis (ADVOCATE)ANCA-Associated VasculitisUnited States, Australia, Belgium, Canada, France, Italy, Japan, Netherlands, Spain, United Kingdom, Austria, Czechia, Denmark, Germany, Hungary, Ireland, New Zealand, Norway, Sweden, Switzerland
-
Second Affiliated Hospital, School of Medicine,...RecruitingANCA Associated VasculitisChina
Clinical Trials on Abatacept (Orencia)
-
Johns Hopkins UniversityBristol-Myers SquibbCompleted
-
Bristol-Myers SquibbCompletedUlcerative ColitisUnited States, Australia, India, Korea, Republic of, Poland, Canada, France, Brazil, Mexico, Puerto Rico, Belgium, Switzerland, Italy, Netherlands, Germany, Ireland, South Africa, United Kingdom, Czech Republic
-
University Medical Center GroningenBristol-Myers SquibbCompletedSjögren's SyndromeNetherlands
-
University of California, Los AngelesBristol-Myers SquibbTerminated
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceCompleted
-
Marmara UniversityThe Scientific and Technological Research Council of TurkeyRecruitingLRBA Deficiency | CTLA4 HaploinsufficiencyTurkey
-
Stuart Knechtle, M.D.TerminatedAutoimmune HepatitisUnited States
-
Bristol-Myers SquibbCompletedRheumatoid ArthritisUnited States
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedMultiple Sclerosis, Relapsing-RemittingUnited States, Canada
-
Washington University School of MedicineBristol-Myers SquibbCompleted